Streetbeat News

TWST

Twist Bioscience Corporation

https://www.twistbioscience.com

Industry

Medical - Diagnostics & Research

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

Open

45.78

Mkt cap

2.7B

Volume

834K

High

46.82

P/E Ratio

-11.92

52-wk high

60.90

Low

45.32

Div yield

N/A

52-wk low

15.85

Twist Bioscience (NASDAQ:TWST) reported Q2 2024 earnings with a smaller loss per share of $(0.79) compared to estimates of $(0.81) and a 24.04% improvement from last year. Sales reached $75.302M, surpassing estimates of $70.655M and marking a 25.13% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:21 pm

Twist Bioscience (NASDAQ:TWST) has received mixed ratings from analysts, with a recent shift towards a more positive outlook. Over the past three months, 5 analysts have provided ratings, with the latest average 12-month price target for TWST being $43.6, marking a significant increase from the previous target of $31. This positive adjustment reflects analysts' growing optimism about the company's performance and market position. Twist Bioscience, a synthetic biology company, has shown a revenue growth rate of 31.81% as of December 31, 2023, despite trailing behind its industry peers. The company's financial health is highlighted by its efficient cost management, impressive ROE and ROA, and a prudent approach to debt management.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 8:00 pm

Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience (NASDAQ:TWST) but has lowered the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 7:25 pm

Cathie Wood's Ark Invest has continued its buying spree of Tesla Inc. (TSLA) shares, acquiring over $14M worth amid a stock price dip. Ark's ETFs, ARK Innovation ETF (ARKK) and ARK Next Generation Internet ETF (ARKW), bought significant amounts of TSLA shares. Additionally, Ark made other key trades, including selling Coinbase Global Inc (COIN) shares and engaging in transactions involving Roblox Corp (RBLX), Robinhood Markets Inc (HOOD), Twist Bioscience Corp (TWST), Personalis Inc (PSNL), UiPath Inc (PATH), and Kratos Defense & Security (KTOS).

Portfolio Pulse from Benzinga Neuro

March 29, 2024 | 2:09 am

Cathie Wood's Ark Invest sold shares of Coinbase and Robinhood worth approximately $6.9 million each, and Nvidia shares valued at $2.15 million, amidst a Bitcoin rally surpassing $56,000. The sales occurred through various ARK ETFs, reflecting adjustments in Ark's investment strategy despite previous positive remarks on Coinbase and Nvidia. Additionally, Ark Invest increased its stakes in ROKU, VCYT, TXG, TWST, and NTLA, indicating a bullish outlook on digital media and biotech sectors.

Portfolio Pulse from Benzinga Neuro

February 27, 2024 | 3:45 am

Cathie Wood's Ark Invest made significant trades, buying $40M in Pinterest (PINS) despite its Q4 revenue miss, and selling shares in Shopify (SHOP) and Nvidia (NVDA). The firm also adjusted its holdings in Twilio (TWLO), Pacific Biosciences (PACB), Twist Bioscience (TWST), and Beam Therapeutics (BEAM), reflecting strategic shifts towards long-term potential and innovation.

Portfolio Pulse from Benzinga Neuro

February 09, 2024 | 4:49 am

Cathie Wood's Ark Invest sold over $2.8 million worth of Nvidia (NVDA) shares amid AI hype and bought $1.3 million worth of Robinhood (HOOD) stock. The sale of Nvidia shares reflects a cautious stance towards its valuation despite its AI potential. Meanwhile, the purchase of Robinhood shares indicates confidence in its financial outlook and fintech industry potential. Ark also adjusted its portfolio by selling UiPath (PATH) shares and buying into Pacific Biosciences (PACB), Twist Bioscience (TWST), 10X Genomics (TXG), and Recursion Pharmaceuticals (RXRX).

Portfolio Pulse from Benzinga Neuro

February 08, 2024 | 3:20 am

Twist Bioscience and Element Biosciences have announced a collaboration to launch 'Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow', which is expected to be available soon. This collaboration aims to enhance genomic research and diagnostics capabilities.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:13 pm

Twist Bioscience Corporation (NASDAQ:TWST) launched the cfDNA Library Preparation Kit for liquid biopsy research, enhancing the detection of tumor variants in degraded or low DNA samples. This addition to Twist's portfolio aims to support the growing field of liquid biopsy applications, including cancer screening and monitoring for minimal residual disease (MRD). The kit is designed for high accuracy and sensitivity, capable of detecting rare allele variants with minimal sample input. It complements Twist's suite of tools for liquid biopsy assay development, including the Twist cfDNA Pan-Cancer Reference Standard v2.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:02 pm

Twist Bioscience (NASDAQ:TWST) received mixed analyst ratings with a notable increase in its 12-month price target to $44.5, up 61.82% from $27.50. Analysts from Scotiabank, Barclays, and Goldman Sachs raised their price targets, reflecting optimism about the company's disruptive DNA synthesis platform and its financial performance, including a 16.82% revenue growth rate and strong profitability metrics despite a negative net margin.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 7:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.